SLABÝ, Ondřej, Marek SVOBODA, Jaroslav MICHÁLEK and Rostislav VYZULA. MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Molecular Cancer. BioMed Central Ltd, 2009, vol. 8, No 102, p. 1-13. ISSN 1476-4598.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name MicroRNAs in colorectal cancer: translation of molecular biology into clinical application
Name in Czech MicroRNAs in colorectal cancer: translation of molecular biology into clinical application
Authors SLABÝ, Ondřej, Marek SVOBODA, Jaroslav MICHÁLEK and Rostislav VYZULA.
Edition Molecular Cancer, BioMed Central Ltd, 2009, 1476-4598.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 4.160
Organization unit Faculty of Medicine
UT WoS 000272282200001
Keywords in English microRNA: colorectal cancer; translational medicine; prognosis; prediction
Tags International impact, Reviewed
Changed by Changed by: prof. RNDr. Ondřej Slabý, Ph.D., učo 42891. Changed: 12/1/2010 15:08.
Abstract
MicroRNAs (miRNAs) are small non-coding RNAs 18-25 nucleotides in length that downregulate gene expression during various crucial cell processes such as apoptosis, differentiation and development. Changes in the expression profiles of miRNAs have been observed in a variety of human tumors, including colorectal cancer (CRC). Functional studies indicate that miRNAs act as tumor suppressors and oncogenes. These findings significantly extend Vogelstein's model of CRC pathogenesis and have shown great potential for miRNAs as a novel class of therapeutic targets. Several investigations have also described the ability of miRNA expression profiles to predict prognosis and response to selected treatments in CRC patients, and support diagnosis of CRC among cancer of unknown primary site. miRNAs' occurrence has been repeatedly observed also in serum and plasma, and miRNAs as novel minimally invasive biomarkers have indicated reasonable sensitivity for CRC detection and compare favorably with the fecal occult blood test. In this review, we summarize the knowledge regarding miRNAs' functioning in CRC while emphasizing their significance in pathogenetic signaling pathways and their potential to serve as disease biomarkers and novel therapeutic targets.
Abstract (in Czech)
MicroRNAs (miRNAs) are small non-coding RNAs 18-25 nucleotides in length that downregulate gene expression during various crucial cell processes such as apoptosis, differentiation and development. Changes in the expression profiles of miRNAs have been observed in a variety of human tumors, including colorectal cancer (CRC). Functional studies indicate that miRNAs act as tumor suppressors and oncogenes. These findings significantly extend Vogelstein's model of CRC pathogenesis and have shown great potential for miRNAs as a novel class of therapeutic targets. Several investigations have also described the ability of miRNA expression profiles to predict prognosis and response to selected treatments in CRC patients, and support diagnosis of CRC among cancer of unknown primary site. miRNAs' occurrence has been repeatedly observed also in serum and plasma, and miRNAs as novel minimally invasive biomarkers have indicated reasonable sensitivity for CRC detection and compare favorably with the fecal occult blood test. In this review, we summarize the knowledge regarding miRNAs' functioning in CRC while emphasizing their significance in pathogenetic signaling pathways and their potential to serve as disease biomarkers and novel therapeutic targets.
Links
NS9814, research and development projectName: Identifikace a studium funkce mikroRNA s prediktivním a prognostickým významen u pacientů se zhoubným novotvarem tlustého střeva a konečníku
PrintDisplayed: 17/8/2024 03:21